Already FDA-cleared and in routine clinical use in Las Vegas, the Dynamis Robotic Surgical System is set for its next evolution, leveraging NVIDIA Jetson Thor, NVIDIA Isaac for Healthcare, and NVIDIA Cosmos platforms to define the future of hard tissue robotic surgery.
LAS VEGAS, NV and BERN, SWITZERLAND / ACCESS Newswire / January 5, 2026 / LEM Surgical, a leader in next-generation hard tissue robotics, today announced its participation in the 2026 Consumer Electronics Show (CES). At this year’s event, LEM is highlighting the commercial success of the Dynamis Robotic Surgical System, the first surgical humanoid optimally adapted to the unique demands of the operating room, while unveiling a strategic roadmap to integrate NVIDIA’s groundbreaking Physical AI tools into its next-generation products.
Unlike traditional surgical robots that operate as static tools, LEM is defining a new category of “Surgical Humanoids.” The Dynamis system is optimally architected to allow two robotic arms to work in coordinated unison, perfectly synchronized with dynamic vision. This architecture mimics the bimanual dexterity and workflow of a human surgeon, delivering a level of adaptability previously unseen in spinal robotics.
Visit LEM Surgical at CES 2026
NVIDIA has chosen LEM Surgical to showcase at their CES exhibition area and invites media, investors, and industry partners to experience the Dynamis Robotic Surgical System and discuss the application of Physical AI in healthcare.
Location: Fontainebleau Las Vegas, 2777 S Las Vegas Blvd, Las Vegas, NV 89109
From Innovation to Routine Standard of Care
While many medical technologies at CES are conceptual, the Dynamis system is a commercial reality. The system is FDA 510(k) cleared and is currently being used routinely for spinal procedures at Southern Hills Hospital in Las Vegas.
The Future: Powered by NVIDIA Physical AI
At CES, LEM Surgical is also revealing its technical roadmap for the next generation of Dynamis, focusing on the integration of NVIDIA physical AI open models, frameworks, and libraries. To achieve unprecedented levels of autonomy and situational awareness, future iterations of the Dynamis system will be powered by NVIDIA Jetson Thor, a computing platform designed specifically for humanoid robotics. Furthermore, LEM Surgical will leverage the NVIDIA Isaac for Healthcare open-source framework and NVIDIA Cosmos open-world foundation models to continuously train its robotic systems, enabling them to learn, adapt, and assist surgeons with superhuman perception.
Yossi Bar, Founder and CEO of LEM Surgical, commented:
“Collaborating with NVIDIA represents a pivotal moment in the evolution of surgery. By advancing physical AI, we aren’t just building machines; we are architecting the future of human-robot collaboration to enhance clinical precision and expand access to life-saving care. NVIDIA stands as a beacon for the entire MedTech industry, signaling a new era where intelligent sensing and automation become a cornerstone of modern medicine.”
About LEM Surgical
LEM Surgical is a visionary MedTech company dedicated to the Quintuple Aim: improving outcomes, enhancing patient and provider satisfaction, ensuring financial sustainability, and advancing health equity. Its flagship product, the Dynamis Robotic Surgical System, is the world’s first surgical humanoid, featuring a multi-arm architecture synchronized with dynamic vision. Headquartered in Bern, Switzerland, with commercial operations in Tampa, Florida, LEM Surgical represents the convergence of Swiss engineering and American commercial innovation. For more information, visit www.lemsurgical.com.
Media Contact: LEM Surgical Corporate Communications communications@lemsurgical.com
Investor Relations: LEM Surgical CFO olaf@lemsurgical.com
************************************************
Forward-Looking Statements
This press release contains forward-looking statements regarding the development of next-generation products, the integration of NVIDIA technologies (Jetson Thor, Isaac, Cosmos), and future capabilities that have not yet received US FDA clearance for use. These statements are based on current expectations and are subject to regulatory clearances and market conditions.
SOURCE: LEM Surgical AG